POS1062 THERAPEUTIC POTENTIAL OF IMVOTAMAB, A CD20-TARGETED BISPECIFIC IGM T CELL ENGAGER, FOR THE TREATMENT OF REFRACTORY AUTOIMMUNE DISEASE PATIENTS
Racquel Domingo-Gonzalez(IGM Biosciences (United States)), M. Harler(IGM Biosciences (United States)), Carrie Brodmerkel(Janssen (United States)), Stephen F. Carroll(IGM Biosciences (United States)), Maya K. Leabman(IGM Biosciences (United States)), Bruce A. Keyt, Genevive Hernandez(Sutro Biopharma (United States)), Kathleen H. Burns(Massachusetts General Hospital), M. F. Kotturi(IGM Biosciences (United States)), R. Kunder(IGM Biosciences (United States)), Kimberly W. Hart(IGM Biosciences (United States)), S. Pandey(IGM Biosciences (United States)), Miho Oyasu(IGM Biosciences (United States)), Albert F. Candia(Dynavax Technologies (United States)), I. Baribaud(IGM Biosciences (United States))
Cited by 9
Related Papers
Vascular Endothelial Growth Factor in Ocular Fluid of Patients with Diabetic Retinopathy and Other Retinal Disorders
|New England Journal of Medicine|1994|3.8k
Patterns of somatic structural variation in human cancer genomes
|Nature|2020|999
Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing
|Nature Genetics|2020|790
Relationship between Plasma Levels of Lipopolysaccharide (LPS) and LPS‐Binding Protein in Patients with Severe Sepsis and Septic Shock
|The Journal of Infectious Diseases|1999|611
Structure of exotoxin A of Pseudomonas aeruginosa at 3.0-Angstrom resolution.
|Proceedings of the National Academy of Sciences|1986|518